The authors developed a new integrated Markov model to assess the cost-effectiveness of vaccines against Lyme disease and tick-borne encephalitis. The model analyzes the long-term efficacy of vaccines in endemic areas. The effectiveness of tick-borne encephalitis vaccines ranges from 90.1% to 98.9%, reaching 98.9% after the third dose and 98.8% after the booster. Vaccines Encepur and FSME-Immun have an efficiency of 95.8% bzw. 90.1%, after the booster it rises to 96.6%. For Lyme disease, clinical trials of the recombinant OspA vaccine showed a 76% reduction in symptomatic disease. The study highlights implications for further research into vaccination against these tick-borne diseases. The model takes into account age groups, where protection over 60 years decreases after only one year. The main finding is the need for further studies to optimize vaccination strategies.